Teva Pharmaceuticals has entered into a commercialization agreement with Samsung Bioepis to obtain exclusive marketing rights in the U.S. for the Soliris biosimilar, Epysqli. This biosimilar is approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and other rare conditions associated with excessive complement system activity.